Shares of PN Gadgil Jewellers jumped 4.2% to ₹612 on the NSE, following a breakout above the Rs 590‑610 trendline, according to Ganesh Dongre of Anand Rathi.
The daily chart shows the MACD slipping into an oversold zone, hinting at a potential momentum swing, while the next resistance cluster sits at ₹605‑₹670, with a decisive close above ₹630 likely to cement bullish bias.
Current buy range sits between ₹600‑₹620, with stop loss at ₹580. Traders already holding can add on dips, and a close above ₹630 would trigger the next target of ₹650‑₹670.
Mankind Pharma trades in the ₹2250‑₹2280 window with a stop at ₹2200 and a target at ₹3380‑₹2450, showing a comparative upside of 48% versus PN Gadgil's 7%.
BEML is consolidating around ₹2060‑₹2080, with a stop at ₹2020 and a target of ₹2280‑₹2350, reflecting a 10% upside potential in a defence‑leaning sector.
Looking ahead, the sector is poised for an uptick in infrastructure spending, and analysts expect PN Gadgil to benefit from a rising jewellery demand cycle, while upcoming earnings will test the 2026 guidance.